

PROVIDER BULLETIN

PROVIDER INFORMATION



October 2, 2023

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-203	Home Non-Invasive Positive Airway Pressure Devices for the Treatment of Respiratory Insufficiency and Failure
MP-714	Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing
MP-732	Testing Serum Vitamin D Levels

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90718	Roctavian (valoctocogene roxaparvovec-rvox)
PH-90714	Rystiggo (rozanolixizumab-noli)
PH-90091	Orencia (abatacept)
PH-90117	Stelara (ustekinumab)
PH-90202	Entyvio (vedolizumab)
PH-90177	Ilaris (canakinumab)
PH-90358	Ilumya (tildrakizumab-asmn)
PH-90111	Sandostatin_LAR (octreotide suspension)
PH-90114	Soliris (eculizumab)
PH-90671	Skyrizi IV (rizankizumab-rzaa)
PH-90291	Spinraza (nusinersen)
PH-90673	Xenpozyme (olipudase-alfa)
PH-90633	Xipere (triamcinolone acetonide injectable suspension)